Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosisJ Neurol 2022 Sep 16;[EPub Ahead of Print], M Chappuis, C Rousseau, E Bajeux, S Wiertlewski, D Laplaud, E Le Page, L Michel, G Edan, A Kerbrat
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.